Colorectal Cancer Awareness Month is approaching in March which highlights the importance of screening and promoting healthy lifestyle habits that can decrease a person’s risk of developing colorectal cancer.

We must Lead the Battle with Patients to improve the survival rates and conquer this disease.

The 5-year survival rate differs according to stage of disease¹:

Advances in the treatment of metastatic colorectal cancer have led to an improvement in survival. Many new cancer drugs target specific molecular aberrations or cell-signalling pathways, but these drugs are only active in a subset of patients due to molecular differences between tumors2. Moreover, colonoscopy polypectomy reduces long term mortality in patients with adenomatous polyps by 53%³.

Personalized medicine has the potential to tailor therapy towards the oncogenic drivers of the tumor and modulate the tumor immune environment⁴.

As per recent data, mOS for Left sided RAS wt mCRC has reached ~40 months with the addition of Erbitux + FOLFOX/FOLFIRI as first line therapy^5,6.